GlycoMimetics Employee Directory

GlycoMimetics corporate office is located in 9708 Medical Center Dr, Rockville, Maryland, 20850, United States and has 1-10 employees.

Employees by Department

Departments

Number of employees

Engineering & Technical

2

Finance

2

Sales

1

Operations

1

Medical & Health

1

GlycoMimetics CEO

Fran Shay, Executive Administrator & President & Chief Executive Officer at GlycoMimetics
United States flag for contact location.
Fran ShayExecutive Administrator & President & Chief Executive Officer
PhonePhoneEmailEmail
See Profile

Key Employees of GlycoMimetics

GlycoMimetics Global Presence

globalPresence illustration
North America1-10
Asia1-10

Index of contact profiles from GlycoMimetics

Hundreds of professionals searching for GlycoMimetics have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
12

Former Employees at GlycoMimetics

Explore people who held key positions, contributed to GlycoMimetics's success, and advanced their careers.

People from Similar Companies in the Manufacturing Industry Located in Maryland, United States

Frequently Asked Questions Regarding GlycoMimetics Employees

How many employees does GlycoMimetics have?
GlycoMimetics has 1-10 employees
Who is the CEO of GlycoMimetics?
GlycoMimetics’s CEO is Fran Shay
Who are GlycoMimetics key employees?
Some of GlycoMimetics key employees are Stephanie Irish, John Peterson
Where is GlycoMimetics located?
GlycoMimetics’s headquarters are located at 9708 Medical Center Dr, Rockville, Maryland, 20850, United States
How do I contact GlycoMimetics?
GlycoMimetics Contact Info: Phone number: (240) 243-1201 Website: www.glycomimetics.com
What does GlycoMimetics do?

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the tr... eatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville,...Read More

Is GlycoMimetics a public company?
GlycoMimetics is private company therefore does not currently have an official ticker symbol
See more information about GlycoMimetics Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.